Hemostemix: Florida Law Opens Door for Stem Cell Therapy Expansion

On July 1, 2025, Florida enacted Senate Bill 1768, a landmark law allowing physicians to offer certain autologous stem cell therapies that are not yet FDA-approved, provided patients give informed consent and the procedures are conducted by licensed professionals.

This regulatory shift creates an immediate opportunity for Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF), a Canadian regenerative medicine company specializing in VesCell/ACP-01, a therapy designed to restore blood flow and promote healing in patients suffering from severe ischemia.

Why This Matters for Hemostemix

Hemostemix has already treated over 498 patients with ACP-01, showing trial results that include smaller ulcer sizes, improved circulation, and reduced amputation rates. With Florida’s new legal framework, the company can now commercialize VesCell in the Sunshine State before FDA approval—potentially accelerating both adoption and revenue. First treatments in Florida are targeted for late 2025, and Hemostemix projects $22.5 million in sales for 2026.

Learning from Other Biotech Breakouts

The biotech sector has a history of companies making exponential gains when innovation meets the right market conditions:

• Exact Sciences rose from ~$2 in 2013 to over $130 at its peak on the success of its Cologuard cancer test.
• Moderna was a relatively unknown small-cap before its mRNA platform propelled its COVID-19 vaccine to global use, driving shares from around $18 to nearly $500.
• Vertex Pharmaceuticals climbed more than 1,000% over a decade by pioneering treatments for cystic fibrosis.
• Regeneron surged over 600% on the blockbuster performance of its eye drug Eylea.
• Novavax went from under $5 to over $300 during the race to produce a COVID-19 vaccine.

Each of these cases involved a scientific breakthrough meeting favorable timing—whether regulatory changes, urgent public health needs, or key clinical results.

The Road Ahead

It’s important to note that VesCell remains investigational, and investment in early-stage biotech carries significant risk. Florida’s new law does not imply FDA approval; rather, it creates a pathway for patients and physicians to access therapies under specific conditions.

For Hemostemix, this legal shift may represent a pivotal moment—much like other inflection points that helped propel biotech companies from obscurity to the forefront of their fields. Whether the company follows that trajectory will depend on clinical performance, market uptake, and investor confidence in the years ahead.

Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.

The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.

Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.

EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.

By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.